Search hospitals > Iowa > Cedar Rapids

Mercy Hospital

Claim this profile
Cedar Rapids, Iowa 52403
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Recurrence
153 reported clinical trials
1 medical researcher
Photo of Mercy Hospital in Cedar RapidsPhoto of Mercy Hospital in Cedar RapidsPhoto of Mercy Hospital in Cedar Rapids

Summary

Mercy Hospital is a medical facility located in Cedar Rapids, Iowa. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Mercy Hospital is involved with conducting 153 clinical trials across 297 conditions. There are 1 research doctors associated with this hospital, such as Deborah W. Wilbur.

Area of expertise

1Cancer
Global Leader
Mercy Hospital has run 53 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Mercy Hospital has run 42 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
ER positive
Stage IV

Top PIs

Clinical Trials running at Mercy Hospital

Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Prostate Cancer
Cancer
Colorectal Cancer
Squamous Cell Carcinoma
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Colon Cancer
Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Mercy Hospital?
Mercy Hospital is a medical facility located in Cedar Rapids, Iowa. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Mercy Hospital is involved with conducting 153 clinical trials across 297 conditions. There are 1 research doctors associated with this hospital, such as Deborah W. Wilbur.